Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8 Other hematologic neoplasm 7 Myeloid 5 Thoracic 4 Head & Neck 3 Gastrointestinal 3 Breast 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Liposarcoma, Myxoid 1 Liposarcoma 1

Interventions

Radiotherapy 220 Doxorubicin 210 Cyclophosphamide 210 Temozolomide 182 Ifosfamide 121 Filgrastim 111 Imatinib Mesylate 104 Etoposide 101 Vincristine 92 Gemcitabine 89 Bevacizumab 83 Magnetic Resonance Spectroscopy 80 Irinotecan 79 pembrolizumab 75 Radiation 69 Carboplatin 65 Methotrexate 62 pazopanib 61 Nivolumab 58 Cisplatin 58 fludarabine phosphate 57 Peripheral Blood Stem Cell Transplantation 57 Surgical Procedures, Operative 56 Specimen Handling 56 Trabectedin 52 Docetaxel 50 Biopsy 50 Busulfan 49 Melphalan 46 Paclitaxel 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pioglitazone × Sarcoma × Clear all

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡